17/09/2025 22:11
|
Medical, Health & Aged Care
* Four-year data show nearly 9 in 10 RMS patients remained free from progression independent of relapse activity (PIRA)
* Results highlight the potential of MAVENCLAD to reduce neurodegeneration...